DIA CALL FOR ABSTRACTS

SUBMISSION DEADLINE: APRIL 19

Digital Technology in Clinical Trials

SHORT COURSES: OCTOBER 27 | VIRTUAL
CONFERENCE: OCTOBER 28-29 | VIRTUAL

Co-Sponsored with Critical Path Institute's ePRO Consortium

CALL FOR SESSIONS, PRESENTATIONS, AND SHORT COURSES

ABSTRACT SUBMISSION DETAILS AND GUIDELINES
SUBMISSION DEADLINE: APRIL 19

Are you a Regulator or Industry professional involved in digital technology in clinical trials? If so, DIA wants to hear from YOU!

Clinical trials are undergoing a transformation that is building on capabilities afforded by the innovation, power, and availability of digital technology and advanced analytics. These technologies and tools are increasing potential for participation and diversity by improving accessibility to representative populations and lessening participant burden, reducing inefficiencies in data collection, and accelerating evidence generation. Collectively, digital technologies have the potential to improve time to market, the patient experience, and ultimately outcomes that matter to patients.

Unprecedented amounts of data can be collected using digital tools and these new technologies require novel approaches to fully leverage their potential. Challenges include:

- Ensuring access for those who may not have infrastructure or literacy required to participate
- A need for data standards
- A skilled workforce
- Privacy and security
- Data management
- Data interoperability
- Leveraging artificial intelligence (AI), machine learning, and other advanced analytics appropriately

The 2021 *Digital Technology in Clinical Trials* conference will provide a unique platform to encourage driving toward solutions to the most pressing challenges posed by the integration of technology throughout the clinical trial ecosystem.

The Program Committee is seeking proposals for Short Courses, Sessions, and Presentations.

Sessions should begin with a presentation that describes either:

1. Where digital technology(ies) has(ve) provided an appropriate solution to a significant challenge in medical product development

   OR

2. Successful implementation of digital technology in clinical trials that has led to a challenge or limitation

Subsequent discussion of lessons learned and/or proposed solutions in a panel format is required. Case examples may be provided by panelists that demonstrate solutions or where gaps exist, and discussion should center around forming new collaborations and approaches to executing solutions. For example, one challenge is that clinical trials are costly and often run over many years. Digital technology, when used appropriately, can add efficiency to shorten time to market and improve patient experience and outcomes. In this example, a presentation to outline the challenge would be followed by a panel discussion of digital solutions and how to overcome challenges with implementing these solutions to improve time to market. **Presentations** without proposed panel discussion may be considered on a case by case basis. **Short Course** proposals with content relevant to the application of digital technology in clinical trials are encouraged.

Broad themes to guide thinking about where or how challenges might arise include:

- Recruitment and Retention
- Impact on Trial Conduct/Clinical Operations
- Clinical Outcome Assessments
- Technology-Derived Endpoints
- Analytics
- Data Security
- Workforce Preparedness
- Data Ownership
- Digital Technology Infrastructure and System Challenges
- Regulatory Interactions
- Quality Compliance Aspects when Implementing Digital Solutions
- Successful Ways of Managing Continuous Data from Digital Technology
- Fit for Purpose – How do You not Drown in Data
- Infrastructure Challenges
- Decentralized Trials

Submission Deadline: April 19

Short Courses: October 27 | Virtual

Conference Dates: October 28-29 | Virtual

Questions: Contact Susan Benedetti, MSOL, Project Manager, at Susan.Benedetti@DIAglobal.org

We look forward to receiving your proposals **by April 19**, and your participation at the conference!

CALL FOR ABSTRACTS

SUBMISSION DEADLINE: APRIL 19

GENERAL SUBMISSION REQUIREMENTS

- All submissions must be submitted online
- For complete submission requirements and to submit your abstract go to DIAglobal.org/Abstracts

SUBMISSION TIPS

- Ideal submissions will contain practical content and shared experiences
- Theoretical topics and content is acceptable, however, it should be supported with proof of concepts and use cases
- Diverse topics and sessions are welcomed and encouraged within the scope of the forum
- Abstracts should be written using clear language and descriptions to provide enough clarity for the selection committee to review and understand

REQUIRED DOCUMENTATION FOR ALL ABSTRACTS

- **Participant Disclosure Information:** All abstract authors must disclose any relevant financial relationships with any commercial interest associated with this activity that exist or have existed within the past 12 months, as well as any discussion of unlabeled or unapproved drugs or devices. If you are proposing an abstract on behalf of the author, as the submitter you will not be asked to disclose. However, should the abstract be accepted, the author will be informed that he or she must complete and submit a Participant Disclosure in order to participate in the program
- All submitters and authors must agree to the DIA Speaker Authorization for Use of Presentation Materials in order for the abstract to be a part of the Program. Accepted abstracts will be available on DIA's website for attendee download.

SUBMISSION GUIDELINES

Submitting a PRESENTATION ABSTRACT (All abstracts must be submitted online)

15-20-minute presentation. Abstract author is considered the presenter (co-presenters are not permitted) and will be responsible for:

- Adhering to the program development guidelines and timelines
- Working with chair and other presenters in creating a balanced program offering that includes a follow-up panel discussion
- Preparing and delivering a PowerPoint presentation

Submitting a SESSION ABSTRACT (All abstracts must be submitted online)

75-minute total session. Abstract author will be responsible for:

- Adhering to the program development guidelines and timelines
- Recruiting speakers and panelists and ensuring good representation/diversity in their selection. Maximum of one speaker per session and up to 3 panelists
- Working with the Session Chair to communicate with speakers regarding their role in the session

Submitting a SHORT COURSE ABSTRACT (All abstracts must be submitted online)

A "hands-on" interactive learning experience in a small group format. A Full Day Short Course consists of 6 hours and 30 minutes of instruction. A Half Day Short Course consists of 3 hours and 15 minutes of instruction. Short courses will have a lead instructor and no more than one (half day) or two (full day) co-instructor(s). Abstract author is considered the Short Course Lead Instructor and will be responsible for:

- Adhering to the program development guidelines and timelines
- Recruiting co-instructors and ensuring good representation/diversity in their selection
- Communicating with co-instructors regarding their role in the short course and reviewing presentation materials (note: PowerPoint presentations are required from each instructor)
- Managing the short course, including the facilitation of audience questions and interactions

SUBMISSION GUIDELINES

The following information will be requested at the time of submission. ***DIAglobal.org/Abstracts***

To streamline your submission process and avoid possible delays, DIA strongly encourages you to submit your abstract as early as possible. **Do not wait until the last day.**

Prepare your abstract in advance of accessing the DIA website. Abstract information should be copied and pasted from a prepared document as plain text. **All of the below fields are required.**

Submitter or Author Information

Prefix:

First Name:

Middle Name:

Last Name:

Name Suffix:

Degrees:

Job Title:

Company:

Country:

Address Line:

City:

State/Province:

Zip/Postal Code:

Phone:

Email:

NOTE: If you are submitting on behalf of author, you are considered the SUBMITTER and will need to complete the required information for yourself and also for the AUTHOR. Submitters will be the contact for author regarding the status of the abstract.

Submit Your Abstract at **DIAglobal.org/Abstracts**